Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of WD-1603 vs Sinemet in Healthy Subjects
NCT03761004Phase 1Completed
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of WD-1603 in Parkinson's disease (PD) (3 arms), sponsored by Shanghai WD Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Jan 2019; status: completed.
02
Drugs
WD-1603
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03761004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761004.